Xencor Inc. Stock
Price
Target price
€11.00
€11.00
1.850%
0.2
1.850%
€22.44
02.04.26 / Stuttgart Stock Exchange
WKN: A1W96L / Symbol: XNCR / Name: Xencor / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Xencor Inc. Stock
There is an upward development for Xencor Inc. compared to yesterday, with an increase of €0.20 (1.850%).
With 15 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
With a target price of 22 € there is a hugely positive potential of 100.0% for Xencor Inc. compared to the current price of 11.0 €.
Pros and Cons of Xencor Inc. in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xencor Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xencor Inc. | 1.850% | 0.000% | 2.913% | 18.436% | -16.535% | -57.937% | -70.839% |
| United Therapeutics | -1.950% | 4.439% | 11.379% | 69.931% | 14.533% | 143.725% | 198.415% |
| Ionis Pharmaceuticals Inc. | 0.830% | 3.150% | -5.094% | 156.386% | -4.591% | 96.634% | 69.428% |
| Novocure Ltd | -2.330% | -10.373% | -20.883% | -44.694% | -19.347% | -83.519% | -91.924% |
Comments
Xencor (XNCR) had its price target raised by Barclays PLC from $26.00 to $27.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor (NASDAQ:XNCR) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor (NASDAQ:XNCR) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $26.00 price target on the stock.
Show more
Ratings data for XNCR provided by MarketBeat